Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| APHP | OTHER |
| Sorbonne University | OTHER |
| Hopitaux Civils de Colmar | OTHER |
| Hopital Foch |
Not provided
Not provided
Not provided
Not provided
To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study. Cases were treated with temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received carbapenem over the effective antibiotic therapy duration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides). |
| |
| Cases | Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Any intervention | Other | No intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of clinical cure | Number of patient in clinical cure is defined as the resolution of fever and symptoms of UTI present at antibiotic initiation (and no new symptoms) and the absence of clinical or microbiological failure. | Day 14 (End of antibiotic treatment according to national recommendations) |
| Measure | Description | Time Frame |
|---|---|---|
| Kinetic of fever defervescence | Median fever calculation | Baseline (day 0), day 3, day 7, day 14 |
| Inflammatory biomarkers | White blood cells (WBC) count (/mm3) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Consecutive adults hospitalized in participating sites for a definite diagnosis of UTI due to an ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems, were eligible for the study if they provided a non-opposition form for retrospective data collection.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mathieu LAFAURIE, M.D | APHP, St Louis Hospital | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| CH Annecy Genevois | OTHER |
Not provided
Not provided
Not provided
| Baseline (day 0), day 3, day 7, day 14 |
| Inflammatory biomarkers | CRP level (mg/l) | Baseline (day 0), day 3, day 7, day 14 |
| Length of hospital stay | Mean duration of hospital stay | 3 months after UTI diagnosis |
| Relapse of UTI | Number of patient with a new UTI diagnosis after the end of antibiotic treatment | 3 months after antibiotic therapy initiation |
| Loss to follow-up, re-hospitalization, and mortality (safety endpoints) | Number of loss to follow-up, re-hospitalization, and mortality | 3 months after antibiotic therapy initiation |